Challenges in developing new tuberculosis vaccines
Memórias do Instituto Oswaldo Cruz · 2025 · 120
DOI: 10.1590/0074-02760240236 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Memórias do Instituto Oswaldo Cruz, 2025. Verfasst von Gabriela Sadigurschi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Departamento de Assuntos Médicos, Estudos Clínicos e Vigilâ…. Hauptthemen laut MEDLINE: Tuberculosis Vaccines, Vaccine Development, Tuberculosis, Mycobacterium tuberculosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tuberculosis (TB) is a preventable and curable disease caused by the bacillus Mycobacterium tuberculosis. In 2022, according to the World Health Organisation (WHO), TB was the second leading cause of death worldwide caused by a single infectious agent, after coronavirus disease (COVID-19). Brazil is ranked among the 30 countries with the highest TB burden. Currently, the neonatal Bacillus Calmette-Guérin (BCG) is the only vaccine against TB and offers significant efficacy against disseminated and meningeal disease in children. However, BCG has a limited efficacy in preventing adult-type cavitary TB, reinforcing the need for a new effective vaccine against pulmonary TB. There are currently over 22 TB vaccines under evaluation in clinical trials worldwide. Despite significant advancements, several challenges persist in developing and producing an effective TB vaccine. These include understanding the immune mechanisms that confer protection against M. tuberculosis, identifying immune correlates of protection, defining immune responses in BCG-vaccinated individuals, establishing efficacy endpoints for TB vaccine trials, and ensuring vaccine safety and effectiveness in individuals with human immunodeficiency virus (HIV), among other obstacles. Therefore, this study aims to explore the key obstacles in developing new TB vaccines and potential strategies to overcome them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos/Bio-Manguinhos, Departamento de Assuntos Médicos, Estudos Clínicos e Vigilância Pós-Registro, Rio de Janeiro, RJ, Brasil.
- Universidade do Estado do Rio de Janeiro, Hospital Universitário Pedro Ernesto, Rio de Janeiro, RJ, Brasil.
Zitieren
APA
Sadigurschi, G., Kuschnir, M. C. C., Dos Santos, E. A. P., da Silva, B. R. A., Marques, C. M. C., de Andrade, R. C., Vianna, C. M., de Barros, D. G., Mazzi, M. T., Lago, E. A., Dos Santos, E. M., & Maia, M. L. S. (2025). Challenges in developing new tuberculosis vaccines. Memórias do Instituto Oswaldo Cruz, 120. https://doi.org/10.1590/0074-02760240236
Vancouver
Sadigurschi G, Kuschnir MCC, Dos Santos EAP, da Silva BRA, Marques CMC, de Andrade RC, et al. Challenges in developing new tuberculosis vaccines. Memórias do Instituto Oswaldo Cruz. 2025;120. doi:10.1590/0074-02760240236
BibTeX
@article{Sadigurschi2025,
author = {Sadigurschi, Gabriela and Kuschnir, Maria Cristina Caetano and Dos Santos, Ewerton Alves Portela and da Silva, Bruno Rangel Antunes and Marques, Celia Menezes Cruz and de Andrade, Raissa Coelho and Vianna, Clarice Monteiro and de Barros, Danillo Gonçalves and Mazzi, Mariana Torres and Lago, Elvira Alonso and Dos Santos, Eliane Matos and Maia, Maria de Lourdes de Sousa},
title = {Challenges in developing new tuberculosis vaccines},
journal = {Memórias do Instituto Oswaldo Cruz},
year = {2025},
volume = {120},
doi = {10.1590/0074-02760240236}
}
EUVIMED